{
    "clinical_study": {
        "@rank": "139360", 
        "arm_group": [
            {
                "arm_group_label": "V0116", 
                "arm_group_type": "Experimental", 
                "description": "One patch per day (during 24 hours) for 21 days"
            }, 
            {
                "arm_group_label": "Reference", 
                "arm_group_type": "Active Comparator", 
                "description": "One patch per day (during 24 hours) for 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety profile of  a repeated application of a\n      new transdermal patch compared to a reference product during 3 weeks, in a large population."
        }, 
        "brief_title": "Nicotine Patch Safety Study", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Smokers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female  aged more than 18 years\n\n          -  Regular smoker motivated to stop tobacco consumption\n\n          -  Current smoker of > or = 20 cigarettes/day and < or = 25 cigarettes/day or Fagerstr\u00f6m\n             score > or = 5 (for smokers between 10 to 20 cigarettes/day)\n\n        Exclusion Criteria:\n\n          -  Any visible skin disorder, abnormal skin pigmentation or other dermatologic disease\n             which, in the opinion of the investigator would interfere with the assessment of the\n             different parameters\n\n          -  Current or past serious chronic cardiovascular, renal, hepatic, gastrointestinal\n             (including duodenal or gastric ulcer), endocrine, hematological, neuropsychiatric,\n             immunosuppressive condition or allergic disease, myopathies, epileptic seizures,\n             bleeding tendency, cancer\n\n          -  History of angina pectoris, myocardial infarction or stroke in the previous 3 months,\n             coronary artery vasospasm, cardiac arrhythmia, acute stroke\n\n          -  Clinically relevant abnormal findings on the physical examination (e.g large scars on\n             the application zone)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655082", 
            "org_study_id": "V00116 TD 2 02", 
            "secondary_id": "2011-005911-94"
        }, 
        "intervention": [
            {
                "arm_group_label": "V0116", 
                "description": "One patch per day (during 24 hours) for 21 days", 
                "intervention_name": "V0116 transdermal patch", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference", 
                "description": "One patch per day (during 24 hours) for 21 days", 
                "intervention_name": "Nicotine transdermal patch", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Central Nervous System Agents", 
                "Nicotine polacrilex", 
                "Nicotine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Smoking cessation", 
            "Nicotine", 
            "Tobacco Use Disorder", 
            "Central Nervous System Agents"
        ], 
        "lastchanged_date": "December 10, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gi\u00e8res", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre - Benite", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rueil - Malmaison", 
                        "country": "France"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Comit\u00e9 de Protection des Personnes", 
                "France: Conseil National de l'Ordre des M\u00e9decins"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluation of local safety (number of subjects with skin irritation / number of subjects by score of adhesiveness) and general safety (number of subjects with emergent adverse events or changes from baseline to end of study in vital signs, electrocardiogram  and clinical laboratory parameters).", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "up to Day 22"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655082"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Visual Analogic Scales (sensations linked to patch application and removal)", 
                "measure": "Sensory profile", 
                "safety_issue": "No", 
                "time_frame": "Day 22"
            }, 
            {
                "description": "Visual Analog Scale Scale and questionnaires", 
                "measure": "Global assessment by the patient", 
                "safety_issue": "No", 
                "time_frame": "Day 22"
            }, 
            {
                "description": "nicotine consumption", 
                "measure": "Subject behaviours", 
                "safety_issue": "No", 
                "time_frame": "up to Day 22"
            }
        ], 
        "source": "Pierre Fabre Medicament", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Medicament", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}